首页> 外文期刊>Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer >The importance of adherence to oral therapies in the field of oncology: The example of breast cancer [L'adhésion thérapeutique aux traitements oraux : enjeux en oncologie - l'exemple du cancer du sein]
【24h】

The importance of adherence to oral therapies in the field of oncology: The example of breast cancer [L'adhésion thérapeutique aux traitements oraux : enjeux en oncologie - l'exemple du cancer du sein]

机译:在肿瘤学领域坚持口服疗法的重要性:乳腺癌的例子[对口服治疗的坚持疗法:肿瘤学的问题-乳腺癌的例子]

获取原文
获取原文并翻译 | 示例
           

摘要

Today, over 40 different oral anticancer therapies are available in the French prescription pricing authority dictionary. Adherence to these therapies has become a major issue in the field of oncology. Most of the available research has focused on adherence to hormonal therapy for breast cancer (BC). The objective of this paper is to synthesize current knowledge on adherence and persistence to hormonal therapy for BC. Available studies display significant heterogeneity due to variability in the measurements and data sources used, as well as in the timing of the measurements. Adherence and persistence estimates have recently been summarized in a meta-regression analysis. For tamoxifen, adherence ranges from 79% at one year to 65% at five years, and for Aromatase Inhibitors (AI), from 80% at one year to 72% at five years. Persistence decreases with the increasing duration of treatment: from a high of 86% of patients persistent at 1 year to a low of 53% at five years for tamoxifen, and from 88% to 69% for AI. Some of the modifiable determinants of adherence are directly linked to the patient-physician relation, to information provided during consultations, or to the specialty of the physician involved in the patient followup. Non-modifiable determinants, such as age or comorbidities, can be used to identify subgroups of patients at high risk of non-adherence in order to target interventions. Few trials have been conducted in oncology to evaluate the efficacy of interventions to improve adherence. Adherence directly impacts both the efficacy of treatment and long-term treatment costs. Interventions to improve adherence to oral therapies should be systematically promoted in oncology. Improving adherence should be considered a priority in the field, lest physicians continue writing inefficient prescriptions for highly efficacious treatments.
机译:如今,法国处方药价格权威词典提供了40多种不同的口服抗癌药物。坚持这些疗法已成为肿瘤学领域的主要问题。现有的大多数研究都集中在坚持激素疗法治疗乳腺癌(BC)。本文的目的是综合有关BC激素治疗依从性和持久性的最新知识。由于测量和所用数据源以及测量时间的差异,现有研究显示出明显的异质性。坚持和持久性估计最近已在元回归分析中进行了总结。他莫昔芬的依从性从一年的79%到五年的65%,而芳香酶抑制剂(AI)的依从性从一年的80%到五年的72%。持续性随着治疗持续时间的增加而降低:他莫昔芬从1年持续的高患者中的86%降低到5年降低至53%的患者,而AI则从88%降低到69%。某些依从性的可更改决定因素直接与患者-医师关系,咨询期间提供的信息或参与患者随访的医师专长直接相关。不可更改的决定因素(例如年龄或合并症)可用于识别发生不依从风险较高的患者亚组,以针对性干预。很少有肿瘤临床试验来评估改善依从性的干预措施的功效。坚持直接影响治疗效果和长期治疗费用。在肿瘤学中应该系统地促进改善对口服疗法依从性的干预。改善依从性应被视为该领域的优先事项,以免医生继续为高效治疗编写低效的处方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号